Azorean Disease of the Nervous System

Azorean Disease of the Nervous System is an inherited brain and nerve disorder that gradually affects balance, walking, speech, and eye movements. The main problem is ataxia, which means “lack of coordination.” Over many years, nerve cells in parts of the brain that control movement—especially the cerebellum and brainstem—slowly wear out. As this happens, a person may walk with a wide, unsteady gait, slur words, have trouble swallowing, feel stiff or shaky, and develop unusual eye movements or trouble moving the eyes. Some people also get weakness, numbness, or muscle wasting in the legs and hands. SCA3 is autosomal dominant, which means a child has a 50% chance of inheriting it if one parent has the faulty gene. The condition is caused by a CAG repeat expansion in the ATXN3 gene (also called ataxin-3). The longer this repeat is, the earlier symptoms tend to start. There is no cure yet, but many symptoms can be managed with rehabilitation, devices, and medicines. Genetic testing can confirm the diagnosis. orpha.net+3NCBI+3NINDS+3

Machado-Joseph disease is an inherited movement disorder. It slowly affects balance, walking, speech, swallowing, eye movements, and sometimes causes stiffness, spasms, tremor, and features that resemble Parkinson’s disease. The nerve cells in the cerebellum, brainstem, and related pathways gradually stop working because an abnormal ataxin-3 protein builds up and harms them. Symptoms usually start in early to mid-adulthood and progress over time. People can still think clearly, but physical tasks become harder. Genetic testing confirms the diagnosis. Care focuses on safety, mobility, communication, nutrition, mood, and sleep, plus treatment of specific symptoms like spasticity, dystonia, neuropathic pain, depression, and parkinsonism. BioMed Central+2orpha.net+2

Other names

This condition has been described by several names in the medical literature. You may see:

• Machado-Joseph disease (MJD)

• Spinocerebellar ataxia type 3 (SCA3)

• Azorean disease or Azorean disease of the nervous system

• Autosomal dominant striatonigral degeneration

• Nigro-spino-dentatal degeneration with nuclear ophthalmoplegia
  All of these refer to the same underlying disorder caused by an ATXN3 CAG-repeat expansion. NCBI+2NCBI+2

Types

Doctors sometimes group SCA3 into clinical subtypes based on the mix of symptoms and the age at which they begin. These types can overlap within the same family.

1. Type 1 (early-onset, “stiff–dystonic–eye” type).
   Starts younger. Often includes marked spasticity (stiff muscles), dystonia (twisting postures), extrapyramidal features (slowness/rigidity), and progressive external ophthalmoplegia (slow or limited eye movements). Balance problems are present but may not be the only feature. orpha.net
2. Type 2 (mixed ataxia type).
   This is common. It combines cerebellar ataxia with variable stiffness, slowness, or tremor. Over time, people may either look more like Type 1 (if stiffness and dystonia dominate) or Type 3 (if peripheral nerve or muscle symptoms dominate). orpha.net
3. Type 3 (late-onset, “ataxia-neuropathy” type).
   Usually starts later in life. Prominent gait ataxia, peripheral neuropathy (numbness, tingling, reduced reflexes), and leg weakness. Speech and swallowing problems may come on gradually. BioMed Central

(Clinicians may also describe additional patterns, but all are part of the SCA3 spectrum linked to ATXN3.) NCBI

Causes

Even though one genetic change causes SCA3, scientists describe “causes” in two useful ways: (1) what starts it (the inherited gene repeat expansion) and (2) what drives damage inside cells (biological mechanisms). Each item below is written in simple terms.

1. ATXN3 CAG-repeat expansion (root cause).
   SCA3 happens when the CAG sequence in the ATXN3 gene repeats too many times. This makes a protein (ataxin-3) with an extra-long “polyglutamine” tail that becomes harmful. NCBI+1

2. Autosomal dominant inheritance.
   Only one changed copy of the gene (from either parent) is enough to cause the disease. Each child has a 50% chance to inherit it. NCBI

3. Repeat-length effect (“anticipation”).
   More repeats usually mean earlier and sometimes faster disease; repeats can expand when passed to the next generation. National Ataxia Foundation

4. Toxic gain-of-function of ataxin-3.
   The expanded ataxin-3 misfolds and does new, harmful things inside nerve cells. PMC

5. Protein aggregation (inclusions).
   Misfolded ataxin-3 sticks together in clumps inside cell nuclei and cytoplasm; these are a marker of damage. OUP Academic

6. Impaired protein quality control.
   Ataxin-3 normally helps tag proteins for removal. The mutant form overloads or hampers the cell’s disposal systems (ubiquitin–proteasome and autophagy), letting damaged proteins build up. PMC

7. Mitochondrial stress.
   Energy makers in cells (mitochondria) function less efficiently, adding strain that can kill fragile neurons. (Mechanistic review data.) PMC

8. Abnormal gene regulation.
   Mutant ataxin-3 can disrupt transcription and other control steps for many genes, changing how neurons work and survive. PMC

9. Axonal transport problems.
   Cargo movement along nerve fibers can slow or fail, starving cell endings of needed supplies. PMC

10. RNA-related toxicity.
    Expanded repeats may also upset RNA handling, adding another layer of stress to cells. PMC

11. Calcium imbalance and excitotoxicity.
    Disturbed calcium flow and over-excitable circuits can injure neurons over time. PMC

12. Post-translational tweaks that worsen misfolding.
    Chemical “tags” added to ataxin-3 (like phosphorylation or ubiquitination) can change how easily it aggregates and spreads. PubMed

13. Nuclear localization of mutant protein.
    When mutant ataxin-3 moves into the nucleus, it forms inclusions and interferes with vital nuclear tasks. OUP Academic

14. Brain-region vulnerability.
    The cerebellum, brainstem, and related pathways are especially sensitive, explaining the ataxia and eye-movement problems. BioMed Central

15. Peripheral nerve involvement.
    Some people develop neuropathy, which adds weakness, numbness, and reduced reflexes to the picture. NCBI

16. Age-related cellular decline.
    Natural wear-and-tear in older neurons lowers the threshold for damage from mutant ataxin-3.

17. Neuroinflammation.
    Support cells in the brain can become over-active, releasing signals that worsen nerve injury. (Mechanistic reviews.) PMC

18. Proteolytic cleavage of mutant protein.
    Enzymes can cut mutant ataxin-3 into smaller fragments that may be even more toxic. PMC

19. Impaired DNA repair/stress responses.
    Cells handle stress signals and DNA maintenance less effectively under the load of mutant protein. PMC

20. Genetic modifiers.
    Other genes can speed up or slow down onset and severity, which is why two people with similar repeat sizes may look different. (Genetic-modifier evidence discussed in reviews.) PMC

Common symptoms

1. Unsteady walking (gait ataxia).
   People lean or sway, take wide steps, and stumble easily, especially in the dark or on uneven ground. NINDS

2. Poor coordination of hands and feet.
   Tasks like buttoning clothes, writing, or picking up small objects become slow and clumsy. NCBI

3. Slurred or slow speech (dysarthria).
   Words sound blurred; sentences may be choppy. Talking takes more effort. NINDS

4. Trouble swallowing (dysphagia).
   Food or liquids “go down the wrong way,” raising the risk of choking or chest infections. NINDS

5. Abnormal eye movements.
   Eyes may jerk (nystagmus), gaze-holding is hard, or the eyes cannot move fully, especially upward or sideways (ophthalmoplegia). NCBI

6. Stiffness and spasticity.
   Legs feel tight; knees may “catch.” This adds to falls and makes walking tiring. NCBI

7. Parkinson-like slowness or rigidity.
   Some people move slowly, with smaller steps and reduced arm swing, similar to parkinsonism. NCBI

8. Dystonia (twisting postures).
   Neck, face, or limbs may twist or pull, sometimes causing painful cramps. NCBI

9. Peripheral neuropathy symptoms.
   Numbness, tingling, burning feet, weak ankles, and reduced reflexes may appear over time. NCBI

10. Muscle wasting (amyotrophy).
    Calf and hand muscles can shrink, making fine tasks and prolonged walking harder. NCBI

11. Tremor.
    Hands may shake at rest or with action, upsetting handwriting and eating. NCBI

12. Bulging or prominent eyes.
    Some people develop a characteristic “bulging eyes” look due to facial muscle changes. NCBI

13. Double vision or blurred vision.
    Because eye movements are limited or jerky, focusing can be hard, especially when looking to the side. NINDS

14. Fatigue and reduced endurance.
    Walking, speaking, and swallowing all require more energy, so people tire easily.

15. Mood or sleep changes.
    Low mood, anxiety, or poor sleep can arise from the burden of symptoms and from brain-circuit changes. (Reported across ataxias; management is important.) NINDS

Diagnostic tests

A) Physical examination (at the clinic)

1. Neurologic exam for ataxia.
   The doctor watches your walk, stance, and finger-to-nose testing to look for cerebellar signs such as swaying, overshooting, and shaky movements. NINDS

2. Eye-movement exam.
   Bedside checks (following a finger, rapid saccades, gaze-holding) find nystagmus or limited eye range typical of SCA3. NCBI

3. Reflex and tone testing.
   Brisk reflexes or spasticity suggest corticospinal involvement; reduced reflexes point toward neuropathy—both patterns can occur in SCA3. NCBI

4. Speech and swallow assessment.
   Listening for dysarthria and checking for cough or throat clearing after sips helps flag dysphagia risk. NINDS

5. Gait and balance scales (SARA/ICARS).
   Structured rating scales track severity over time and guide therapy needs. (Common in ataxia clinics.) NINDS

B) Manual / bedside functional tests

6. Romberg and tandem stance.
   Standing with feet together or heel-to-toe exposes sway and balance loss typical of ataxia.

7. Finger-to-nose and heel-to-shin.
   These coordination tasks reveal overshoot and tremor linked to cerebellar dysfunction.

8. Timed 25-foot walk or 10-meter walk.
   Speed and stability measures help follow progression and rehab response.

9. Bedside dysphagia screen.
   Small sips or spoon tests identify coughing, wet voice, or throat clearing that suggest unsafe swallowing.

10. Hand function checks (nine-hole peg or rapid alternation).
    Simple tasks track hand coordination in the clinic or therapy gym.

C) Laboratory and pathological tests

11. Genetic test for ATXN3 CAG repeats (definitive).
    A blood test counts the CAG repeats in ATXN3. Too many repeats confirm SCA3 in someone with compatible symptoms or a family history; it also allows testing of at-risk adults with counseling. NCBI+1

12. Genetic counseling session.
    A trained counselor explains inheritance (50% risk to children), testing options, privacy, and family planning. NCBI

13. Rule-out blood tests.
    Basic labs (B-12, thyroid, vitamin E, copper, autoimmune screens) search for other, treatable causes of ataxia to avoid missing something fixable.

14. Sleep and aspiration labs when needed.
    If nighttime breathing or aspiration is suspected, clinicians may order tests tied to respiratory or swallow safety (see tests below). NINDS

D) Electrodiagnostic tests

15. Nerve conduction studies (NCS).
    These measure how quickly and strongly signals travel along nerves; slow signals or low amplitudes support peripheral neuropathy in SCA3. NCBI

16. Electromyography (EMG).
    A fine needle records muscle activity; EMG can show signs of denervation or muscle involvement, clarifying why weakness or cramps occur. NCBI

17. Video-oculography (eye movement recording).
    Special cameras precisely record saccades and gaze-holding, which helps document SCA3-type oculomotor patterns. NCBI

18. Polysomnography (sleep study) when indicated.
    If there are symptoms of sleep apnea or abnormal movements at night, a sleep study documents problems and guides treatment (e.g., CPAP). (Common across neurodegenerative ataxias.) NINDS

E) Imaging tests

19. MRI of the brain.
    MRI may show cerebellar and brainstem atrophy—a shrinkage pattern that supports SCA3, though MRI alone cannot prove it. Imaging also rules out strokes, tumors, or inflammation that can mimic ataxia. BioMed Central

20. Spinal MRI (select cases).
    If there is unusual stiffness, sensory level, or bowel/bladder change, spinal MRI checks for compression or other causes that could add to gait problems (important for safety and management).

Non-pharmacological treatments (therapies & others)

1) Coordinative/balance-focused physical therapy (PT).
Purpose: Improve gait, stance, fall safety.
Mechanism: Targeted exercises train posture, trunk control, limb coordination, and vestibular compensation; neuroplasticity helps remaining circuits work better. Programs usually combine static/dynamic balance drills, gait practice, and home exercise. Evidence in hereditary ataxias supports multi-week, intensive, task-specific PT to improve SARA gait/stance items. Wiley Online Library

2) Vestibular rehabilitation.
Purpose: Reduce dizziness and unsteadiness.
Mechanism: Repeated head/eye movement exercises drive vestibulo-ocular reflex adaptation and sensory re-weighting so vision and proprioception better support balance. Wiley Online Library

3) Strength and endurance training (aerobic + resistance).
Purpose: Maintain walking capacity and delay deconditioning.
Mechanism: Improves muscle power, cardiovascular reserve, and fatigue tolerance; supports safer transfers and fall recovery. Wiley Online Library

4) Task-oriented gait training with body-weight support/treadmill.
Purpose: Practice efficient, repetitive steps in a controlled environment.
Mechanism: High-repetition stepping promotes central pattern refinement and better foot placement. Wiley Online Library

5) Occupational therapy (OT) & adaptive devices.
Purpose: Optimize daily living tasks and independence.
Mechanism: Home and task modifications (grab bars, bath seats, weighted utensils, writing aids), energy-conservation strategies, and fall-prevention planning reduce risk and effort. NORD

6) Speech-language therapy for dysarthria.
Purpose: Clearer speech and communication strategies.
Mechanism: Respiratory-phonatory drills, pacing, over-articulation, and assistive communication tools. pubs.asha.org

7) Swallowing therapy for dysphagia.
Purpose: Safer eating; prevent aspiration.
Mechanism: Postural strategies (chin tuck), texture modification, effortful swallow, and caregiver training; FEES/VFSS helps tailor plans. SAGE Journals

8) Eye-movement/vision strategies.
Purpose: Ease oscillopsia and reading problems from ocular motor signs.
Mechanism: Visual fixation techniques, larger print, line guides; some nystagmus responds to targeted rehab plus medication if needed. NORD

9) Splinting, orthoses, and seating systems.
Purpose: Support posture, reduce contractures, improve safety.
Mechanism: Ankle-foot orthoses, custom seating, and night splints maintain alignment and reduce energy cost. NORD

10) Fall-proofing the home.
Purpose: Reduce injury risk.
Mechanism: Remove trip hazards, use non-slip mats, install lighting/handrails, and keep frequently used items within reach. NORD

11) Driver safety assessment & community mobility.
Purpose: Safe transport planning as coordination declines.
Mechanism: Formal driving evaluations and transition to alternative transport when needed. NORD

12) Energy management & fatigue pacing.
Purpose: Reduce “boom-and-bust” cycles.
Mechanism: Activity scheduling, rest breaks, and prioritizing high-value tasks. NORD

13) Nutrition support with texture-modified diets.
Purpose: Maintain weight and hydration; reduce aspiration.
Mechanism: Dietitians tailor soft/pureed diets and thickened liquids when indicated. SAGE Journals

14) Mental health care (CBT/counseling).
Purpose: Treat depression/anxiety; support coping.
Mechanism: Cognitive behavioral strategies improve mood, sleep, and adherence to rehab. NORD

15) Sleep hygiene and apnea screening.
Purpose: Improve daytime function and cognition.
Mechanism: Regular schedule, dark/quiet room, screen limits; evaluate snoring/apnea. NORD

16) Genetic counseling for family planning.
Purpose: Understand inheritance (autosomal-dominant) and testing options.
Mechanism: Counselors explain risk, predictive testing, and reproductive options. BioMed Central

17) Community/peer support & disease education.
Purpose: Reduce isolation; share practical tips.
Mechanism: Patient organizations (e.g., National Ataxia Foundation) connect families to resources. National Ataxia Foundation

18) Swallow safety equipment & oral care.
Purpose: Lower pneumonia risk.
Mechanism: Suction toothbrushes, frequent oral hygiene, and caregiver training reduce bacterial load and aspiration complications. ResearchGate

19) Falls clinic & bone health.
Purpose: Prevent fractures.
Mechanism: Vitamin D evaluation, hip protectors, and balance programs reduce injurious falls. Wiley Online Library

20) Advance care planning.
Purpose: Align future care with patient goals.
Mechanism: Early conversations about feeding choices (e.g., PEG), mobility, and communication supports. PMC

---

Drug treatments

Important: Most drugs below are symptom-targeted and may be used off-label in SCA3; dosing must be individualized by the treating clinician.

1) Baclofen (oral).
Class: Antispastic muscle relaxant. Dose/Time: Often 5–10 mg three times daily, titrate. Purpose: Reduce spasticity, cramps. Mechanism: GABA_B agonist in spinal cord; decreases excitatory transmission. Side effects: Sleepiness, weakness, dizziness; abrupt stop risks withdrawal. FDA labeling supports spasticity use (oral and intrathecal). DailyMed

2) Tizanidine.
Class: α2-adrenergic agonist antispastic. Dose/Time: 2–4 mg up to three times daily; careful titration. Purpose: Spasticity relief. Mechanism: Presynaptic inhibition of motor neurons. Side effects: Sedation, hypotension, dry mouth; CYP1A2 interactions. FDA Access Data

3) OnabotulinumtoxinA (Botox).
Class: Neuromuscular blocker. Dose/Time: Injected every ~12 weeks. Purpose: Focal dystonia, blepharospasm, severe spasticity, sialorrhea (product-specific). Mechanism: Blocks acetylcholine release at neuromuscular junctions. Side effects: Local weakness, dysphagia risk if injected near bulbar muscles. FDA Access Data

4) IncobotulinumtoxinA (Xeomin).
Class: Botulinum toxin A. Dose/Time: Tailored by muscles; re-dose ~12 weeks. Purpose: Cervical dystonia, blepharospasm, chronic sialorrhea (labeled). Mechanism: ACh release blockade. Side effects: Dry mouth, dysphagia; spread-of-effect warnings. FDA Access Data

5) RimabotulinumtoxinB (Myobloc).
Class: Botulinum toxin B. Dose/Time: Injection; retreat ~12 weeks. Purpose: Cervical dystonia, sialorrhea in adults. Mechanism: Inhibits ACh release. Side effects: Dry mouth, dysphagia, weakness. FDA Access Data

6) Levodopa/carbidopa (Sinemet).
Class: Dopaminergic. Dose/Time: e.g., 25/100 mg three to four times daily; adjust. Purpose: For SCA3 patients with parkinsonian features, levodopa can help for years. Mechanism: Replaces dopamine; carbidopa limits peripheral conversion. Side effects: Nausea, dyskinesia, hypotension. FDA Access Data+1

7) Carbidopa/levodopa intestinal gel (Duopa).
Class: Continuous dopaminergic infusion (via PEG-J). Dose/Time: Up to 2000 mg levodopa over 16 h/day. Purpose: For advanced PD-like fluctuations; occasionally considered in severe levodopa-responsive parkinsonism. Mechanism: Stable levodopa levels reduce “off” time. Side effects: Device/procedure complications, dyskinesia. FDA Access Data

8) Amantadine / extended-release amantadine.
Class: NMDA antagonist/dopaminergic. Dose/Time: 100 mg bid (IR) or labeled ER regimens. Purpose: Reduce dyskinesia, aid fatigue. Mechanism: Glutamate modulation. Side effects: Livedo reticularis, confusion, insomnia. FDA Access Data+1

9) Clonazepam.
Class: Benzodiazepine. Dose/Time: 0.25–0.5 mg at night; titrate. Purpose: Myoclonus, REM behavior disorder, anxiety. Mechanism: GABA_A potentiation. Side effects: Sedation, falls, dependence. FDA Access Data

10) Propranolol.
Class: β-blocker. Dose/Time: 10–60 mg tid or ER daily; monitor BP/HR. Purpose: Action tremor (when present). Mechanism: Peripheral β-adrenergic blockade dampens tremor amplitude. Side effects: Bradycardia, fatigue, bronchospasm in asthma. FDA Access Data

11) Primidone.
Class: Barbiturate-related anticonvulsant. Dose/Time: Start low (e.g., 25–50 mg nightly), titrate. Purpose: Tremor control in select patients. Mechanism: GABAergic inhibition. Side effects: Sedation, ataxia, dizziness. FDA Access Data

12) Gabapentin.
Class: Calcium-channel modulator. Dose/Time: 300 mg nightly → titrate to 900–1800 mg/day. Purpose: Neuropathic pain, cramps. Mechanism: α2δ-subunit modulation reduces excitatory neurotransmission. Side effects: Somnolence, edema, dizziness. FDA Access Data

13) Pregabalin.
Class: Calcium-channel modulator. Dose/Time: 75–150 mg bid; max 450 mg/day for neuropathic pain. Purpose: Neuropathic pain, anxiety. Mechanism: α2δ modulation. Side effects: Dizziness, edema, weight gain. FDA Access Data

14) Duloxetine.
Class: SNRI antidepressant/analgesic. Dose/Time: 30–60 mg daily. Purpose: Depression/anxiety; neuropathic pain. Mechanism: 5-HT/NE reuptake inhibition → descending pain inhibition. Side effects: Nausea, insomnia, blood pressure changes. FDA Access Data

15) Sertraline.
Class: SSRI antidepressant. Dose/Time: 25–100 mg daily. Purpose: Depression, anxiety common in chronic neurologic illness. Mechanism: Serotonin reuptake inhibition. Side effects: GI upset, sleep changes, sexual dysfunction. FDA Access Data

16) Modafinil.
Class: Wakefulness-promoting agent. Dose/Time: 100–200 mg morning. Purpose: Excessive daytime sleepiness/fatigue. Mechanism: Promotes cortical arousal via dopaminergic and other pathways. Side effects: Headache, anxiety, insomnia; rare rash. FDA Access Data

17) Glycopyrrolate oral solution (Cuvposa).
Class: Anticholinergic. Dose/Time: Titrated oral solution. Purpose: Sialorrhea (drooling). Mechanism: Blocks muscarinic receptors in salivary glands. Side effects: Dry mouth, constipation, urinary retention, confusion risk in elderly. FDA Access Data

18) Riluzole (off-label for ataxia).
Class: Glutamate release inhibitor. Dose/Time: 50 mg bid (ALS label). Purpose: Some studies suggested improvements on ataxia scales; others negative—evidence mixed. Mechanism: Reduces excitotoxicity. Side effects: Liver enzyme elevation, dizziness, nausea. NeurologyLive+1

19) Botulinum toxin for sialorrhea/dystonia (A or B formulations).
Class: Neuromuscular blocker. Dose/Time: Tailored injections every ~12 weeks. Purpose: Drooling, cervical dystonia, blepharospasm. Mechanism: ACh release blockade; reduces gland output or overactive muscles. Side effects: Local weakness, dry mouth. FDA Access Data+1

20) Levodopa add-ons (as clinically judged).
Class: Dopaminergic adjuncts. Examples: Careful trials of amantadine for dyskinesia or consideration of continuous therapies when parkinsonism dominates. Purpose & mechanism: Optimize dopaminergic tone in levodopa-responsive SCA3 phenotypes. Key caution: These PD-oriented options are not disease-modifying for SCA3. BrainFacts+1

---

Dietary molecular supplements

1) Coenzyme Q10 (CoQ10).
Dose: Often 100–300 mg/day in studies. Function/Mechanism: Mitochondrial electron transport cofactor; antioxidant. Observational and small data suggest association with better outcomes in SCAs, but progression rates were unchanged in short follow-up; stronger trials are needed. PMC

2) Vitamin E (only if deficient).
Dose: High doses (e.g., 800–1500 mg/day) in vitamin-E deficiency ataxias improve or stabilize signs; not proven for SCA3 without deficiency. Mechanism: Antioxidant membrane protection. ataxia.org.uk+1

3) N-acetylcysteine (NAC).
Dose: Common oral ranges 600–1200 mg/day in other neurologic contexts. Mechanism: Glutathione precursor; antioxidative and anti-inflammatory effects; clinical data in ataxias are limited/mixed. Frontiers+1

4) Omega-3 fatty acids (EPA/DHA).
Dose: ~1–2 g/day combined EPA/DHA. Mechanism: Anti-inflammatory membrane effects; general neuroprotective rationale, but SCA3-specific data are lacking. (Use as supportive nutrition.) NORD

5) Creatine.
Dose: 3–5 g/day. Mechanism: Energy buffering in muscle/brain; limited disease-specific evidence; may support conditioning with exercise. Wiley Online Library

6) B-complex (B1, B6, B12) when low.
Dose: Replace documented deficiencies. Mechanism: Cofactors for neuronal metabolism; treat deficiency-related neuropathy features, not the genetic ataxia itself. NORD

7) Vitamin D (if low).
Dose: Per labs/clinical guidance. Mechanism: Bone health; lowers fall-fracture risk with PT and fall prevention. Wiley Online Library

8) Magnesium (for cramps if low).
Dose: Replace deficiency; avoid overuse in renal disease. Mechanism: Neuromuscular stability. NORD

9) Antioxidant-rich diet pattern (Mediterranean-style).
Mechanism: Emphasizes whole foods, fiber, and polyphenols; supports overall cardiometabolic health during long-term disability; disease-specific evidence is limited. NORD

10) CoQ10 analogs (e.g., idebenone) — investigational context.
Note: In Friedreich ataxia, mixed/negative results in larger trials; not established for SCA3. PubMed+1

---

Drugs for “immunity booster / regenerative / stem-cell

1) Antisense oligonucleotides (ASOs) targeting ATXN3.
Mechanism: Lower mutant ataxin-3 expression; rescued phenotypes in SCA3 mouse models. Human trials are anticipated/early. Dose: Research-protocol only. PMC+1

2) CRISPR/Cas-based ATXN3 gene editing (preclinical).
Mechanism: Inactivate or correct mutant gene; promising animal data; clinical use not yet available. BioRxiv+1

3) Mesenchymal stem cell (MSC) therapy.
Mechanism: Immune modulation, trophic support; early human studies suggest safety, with signals needing confirmation; Phase II programs reported. Dose: Trial protocols only. PMC+1

4) Anti-neuroinflammatory strategies (microglia-modulating agents).
Mechanism: Target microglial activation seen in SCA3 tissues/animal models; still preclinical/early translational. Dose: Research only. PMC+1

5) Novel small-molecule neuroprotectants (experimental).
Mechanism: Reduce oxidative stress or toxic protein handling in SCA3 models; not yet proven clinically. ScienceDirect

6) Exosome/biologic delivery platforms (preclinical).
Mechanism: Enhance delivery of gene or trophic therapies to cerebellum/brainstem. Status: Early research. OUP Academic

---

Surgeries/procedures

1) Percutaneous endoscopic gastrostomy (PEG).
Why: Severe dysphagia with weight loss or recurrent aspiration risk. What: A feeding tube is placed into the stomach to maintain nutrition/hydration and lower pneumonia risk versus long-term nasogastric tubes, though saliva aspiration can still occur. PMC+2PMC+2

2) Intrathecal baclofen (ITB) pump implantation.
Why: Severe, refractory spasticity causing pain, falls, or care difficulty. What: A programmable pump delivers baclofen into spinal fluid, providing strong antispastic effect at lower systemic doses; requires screening test, surgical implantation, and maintenance. FDA Access Data+1

3) Deep brain stimulation (DBS) for refractory tremor/dystonia (case-by-case).
Why: Disabling tremor/dystonia unresponsive to medication. What: Electrodes placed in targets like VIM thalamus or zona incerta can reduce tremor; evidence in cerebellar tremor is limited to case series/case reports. MDPI+2PMC+2

4) Botulinum toxin procedures (office-based injections).
Why: Focal dystonia, blepharospasm, or drooling. What: Targeted injections weaken overactive muscles or reduce salivary output; repeat every ~12 weeks. FDA Access Data+1

5) Airway protection interventions (rare, advanced).
Why: Recurrent aspiration with respiratory compromise. What: Multidisciplinary decisions may include temporary feeding/airway strategies aligned with patient goals. PMC

---

Preventions

1. Early PT/OT to slow deconditioning and teach fall-safe movement. Wiley Online Library

2. Home fall-proofing and caregiver training. NORD

3. Swallow screening and diet texture changes at first signs of choking. SAGE Journals

4. Oral care twice daily to reduce aspiration pneumonia risk. ResearchGate

5. Vision strategies for oscillopsia/eye movement issues. NORD

6. Mood/sleep care to maintain activity and adherence. NORD

7. Bone health (vitamin D if low; balance training). Wiley Online Library

8. Avoid excess alcohol/sedatives that worsen ataxia and falls. NORD

9. Genetic counseling for family planning/testing. BioMed Central

10. Vaccinations & respiratory hygiene to reduce pneumonia complications with dysphagia. SAGE Journals

---

When to see doctors

• New choking, weight loss, frequent cough after meals, or chest infections (aspiration risk). PMC

• Falls, new severe stiffness/spasms, or painful cramping needing antispastic treatment. FDA Access Data

• Rapidly worsening tremor or dystonia that disrupts daily tasks (consider injections or DBS evaluation). MDPI

• New depression, anxiety, or sleep problems affecting function. NORD

• Family planning or questions about genetic risk/testing. BioMed Central

• Interest in research trials (gene-targeted or cell-based) to discuss eligibility and risks. National Ataxia Foundation

---

Foods & habits: what to eat / what to avoid

• Eat: Soft, moist, nutrient-dense foods if swallowing is difficult (e.g., smoothies, yogurt, soft fruits, stews). Why: Lower choking risk while preserving calories. SAGE Journals

• Eat: High-fiber whole foods and adequate fluids. Why: Prevent constipation from immobility and medications. NORD

• Eat: Balanced Mediterranean-style pattern (vegetables, legumes, nuts, fish, olive oil). Why: General cardiometabolic support. NORD

• Eat: Sufficient protein to protect muscle mass alongside PT. Why: Supports rehab gains. Wiley Online Library

• Avoid/limit: Alcohol and sedatives. Why: Worsen ataxia, balance, and speech; increase falls. NORD

• Avoid: Dry, crumbly foods if dysphagia (e.g., crackers) unless modified. Why: Aspiration risk. SAGE Journals

• Avoid: Eating when fatigued or rushing. Why: Raises choking risk; use small bites and pacing. SAGE Journals

• Consider: Thickened liquids if advised after swallow study. Why: Safer bolus control. SAGE Journals

• Consider: Dietitian referral for calorie-dense meal plans. Why: Prevent weight loss. SAGE Journals

• Maintain: Oral hygiene after meals. Why: Lowers bacterial load that can be aspirated. ResearchGate

---

FAQs

1) Is “Azorean disease” the same as SCA3/Machado-Joseph disease?
Yes. “Azorean disease” was an early name; today it is recognized as SCA3/MJD. Karger Publishers+1

2) What causes it?
A CAG-repeat expansion in ATXN3 that produces toxic ataxin-3 protein and harms cerebellar/brainstem circuits. BioMed Central

3) How is it inherited?
Autosomal dominant—each child of an affected parent has a 50% chance of inheriting the expanded gene. BioMed Central

4) What are common symptoms?
Gait and stance ataxia, dysarthria, dysphagia, oculomotor problems, pyramidal signs, dystonia/spasticity, sometimes parkinsonism, neuropathy, and pain. NCBI

5) Is there a cure?
No cure yet; treatment is supportive. Gene-targeted therapies (ASOs/CRISPR) and cell therapies are in research. PMC+2BioRxiv+2

6) Can levodopa help?
Yes, for people with parkinsonian features of SCA3, levodopa can help for years; it does not stop disease progression. BrainFacts

7) Which rehab works best?
Intensive, task-specific balance and coordination therapy with home exercise has the best evidence among non-drug options. Wiley Online Library

8) What about riluzole?
Trials show mixed results—some early signals, others negative. It is not approved for ataxia. NeurologyLive+1

9) Are botulinum toxin injections helpful?
Yes for focal dystonia, blepharospasm, and sialorrhea. Effects are temporary (about 3 months). FDA Access Data

10) When should a feeding tube be considered?
If recurrent aspiration, weight loss, or dehydration occurs despite therapy and diet changes. PEG reduces pneumonia risk versus long-term NG tubes but doesn’t eliminate saliva aspiration. PMC+1

11) Does CoQ10 help?
Data are limited; observational work suggests association with better outcomes, but firm disease-modifying benefit isn’t proven. PMC

12) Can exercise worsen ataxia?
Appropriate, supervised PT improves safety and function; overexertion without support can increase falls. Wiley Online Library

13) Why is oral care emphasized?
Poor oral hygiene increases pneumonia risk in dysphagia; cleaning after meals reduces aspiration of pathogens. ResearchGate

14) Are mood problems part of SCA3?
Depression/anxiety are common in chronic neurologic illness; treat with counseling and, where appropriate, medication. NORD

15) Where can I find trials and updates?
Check reputable foundations and trial registries focused on SCA3/MJD. National Ataxia Foundation

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 15, 2025.